Salemonline Journal

Benign Prostatic Hyperplasia (BPH) Market Size Analysis, Growth Opportunities, Pipeline Development Activities, Emerging Therapies, and Epidemiology Forecast | Key Companies – Dongkook Pharmaceutical,

 Breaking News
  • No posts were found

Benign Prostatic Hyperplasia (BPH) Market Size Analysis, Growth Opportunities, Pipeline Development Activities, Emerging Therapies, and Epidemiology Forecast | Key Companies – Dongkook Pharmaceutical,

June 08
23:08 2022
Benign Prostatic Hyperplasia (BPH) Market Size Analysis, Growth Opportunities, Pipeline Development Activities, Emerging Therapies, and Epidemiology Forecast | Key Companies - Dongkook Pharmaceutical,
DelveInsight’s “Benign Prostatic Hyperplasia (BPH) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Benign Prostatic Hyperplasia (BPH), historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia (BPH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Benign Prostatic Hyperplasia (BPH) Market Insights, Epidemiology, and Market Forecast-2032”. 

 

DelveInsight’s “Benign Prostatic Hyperplasia (BPH) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Benign Prostatic Hyperplasia (BPH), historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia (BPH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

 

Some of the key facts of the Benign Prostatic Hyperplasia (BPH) Market Report: 

  • As per a study conducted by Lim et al. (2017), the histological prevalence of BPH was observed as 8%, 50%, and 80% in the 4th, 6th, and 9th decades of life, respectively 
  • BPH is the most common prostate problem for men older than age 50
  • BPH is more common in older males as compared to those below 40 years 
  • A study conducted by Lee et al. (2017), showed that the median point prevalence of BPH was 25.2%. The study also showed that there was an increasing prevalence of lower urinary tract symptoms (LUTS)/BPH with age 
  •  

Request a sample for the Report: https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market

 

Key benefits of the report:

  1. Benign Prostatic Hyperplasia (BPH) market report covers a descriptive overview and comprehensive insight of the Benign Prostatic Hyperplasia (BPH) Epidemiology and Benign Prostatic Hyperplasia (BPH)  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Benign Prostatic Hyperplasia (BPH) market report provides insights on the current and emerging therapies.
  3. Benign Prostatic Hyperplasia (BPH) market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Benign Prostatic Hyperplasia (BPH) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Benign Prostatic Hyperplasia (BPH) market.

 

Got queries? Click here to know more about the Benign Prostatic Hyperplasia (BPH) Market Landscape 

 

Benign Prostatic Hyperplasia (BPH) Overview

Benign prostatic hyperplasia—also called BPH—is a condition in men in which the prostate gland is enlarged and not cancerous. Benign prostatic hyperplasia is also called benign prostatic hypertrophy or benign prostatic obstruction. As the prostate enlarges, the gland presses against and pinches the urethra. The bladder wall becomes thicker. Eventually, the bladder may weaken and lose the ability to empty completely, leaving some urine in the bladder. The narrowing of the urethra and urinary retention—the inability to empty the bladder completely—cause many of the problems associated with benign prostatic hyperplasia. 

The cause of benign prostatic hyperplasia is not well understood; however, it occurs mainly in older men. Benign prostatic hyperplasia does not develop in men whose testicles were removed before puberty. For this reason, some researchers believe factors related to the testicles may cause benign prostatic hyperplasia. Scientific studies have suggested that benign prostatic hyperplasia may occur because the higher proportion of estrogen within the prostate increases the activity of substances that promote prostate cell growth. 

 

Benign Prostatic Hyperplasia (BPH) Symptoms:

The symptoms of Benign Prostatic Hyperplasia include –

  • Frequent need to urinate
  • Difficulty in urinating
  • Weak urine stream
  • Inability to empty the bladder
  • Dibbling at the end of urination 

 

Benign Prostatic Hyperplasia (BPH) Market  

The dynamics of the Benign Prostatic Hyperplasia (BPH) market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as QLT0074, PRX302, and others during the forecasted period 2019-2032. 

Learn more by requesting for sample @Benign Prostatic Hyperplasia (BPH) Market Landscape

 

Benign Prostatic Hyperplasia (BPH) Pipeline Therapies:

  • Tadalafil
  • PRX302
  • Tamsulosin OCAS
  • QLT0074
  • Silodosin 

 

Benign Prostatic Hyperplasia (BPH) Pipeline Key Companies:

  • Dongkook Pharmaceutical
  • ICOS Corporation
  • Mundipharma Research
  • Astellas Pharma

 

Table of Contents 

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Benign Prostatic Hyperplasia (BPH) Patient Share (%) Overview at a Glance

5. Benign Prostatic Hyperplasia (BPH) Market Overview at a Glance

6. Benign Prostatic Hyperplasia (BPH) Disease Background and Overview

7. Benign Prostatic Hyperplasia (BPH) Epidemiology and Patient Population

8. Country-Specific Patient Population of Benign Prostatic Hyperplasia (BPH) 

9. Benign Prostatic Hyperplasia (BPH) Current Treatment and Medical Practices

10. Unmet Needs

11. Benign Prostatic Hyperplasia (BPH) Emerging Therapies

12. Benign Prostatic Hyperplasia (BPH) Market Outlook

13. Country-Wise Benign Prostatic Hyperplasia (BPH) Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Benign Prostatic Hyperplasia (BPH) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight 

 

To know more about our Competitive Services, Click here: Pharma Competitive Intelligence

https://www.delveinsight.com/consulting/competitive-intelligence-services

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

Related Articles